The translation of cell-based therapies: clinical landscape and manufacturing challenges

Thomas R.J. Heathman, Alvin W. Nienow, Mark J. McCall, Karen Coopman, Bo Kara, Christopher J. Hewitt*

*Corresponding author for this work

Research output: Contribution to journalArticle

Abstract

Cell-based therapies have the potential to make a large contribution toward currently unmet patient need and thus effective manufacture of these products is essential. Many challenges must be overcome before this can become a reality and a better definition of the manufacturing requirements for cell-based products must be obtained. The aim of this study is to inform industry and academia of current cell-based therapy clinical development and to identify gaps in their manufacturing requirements. A total of 1342 active cell-based therapy clinical trials have been identified and characterized based on cell type, target indication and trial phase. Multiple technologies have been assessed for the manufacture of these cell types in order to facilitate product translation and future process development.

Original languageEnglish
Pages (from-to)49-64
Number of pages16
JournalRegenerative medicine
Volume10
Issue number1
Early online date1 Apr 2015
DOIs
Publication statusPublished - 2015

Fingerprint

Cell- and Tissue-Based Therapy
Industry
Clinical Trials
Technology

Bibliographical note

This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License.

Funding: EPSRC

Keywords

  • bioreactor
  • cell-based therapy
  • clinical trials
  • manufacture
  • MSC
  • regenerative medicine
  • stem cell
  • translation

Cite this

Heathman, T. R. J., Nienow, A. W., McCall, M. J., Coopman, K., Kara, B., & Hewitt, C. J. (2015). The translation of cell-based therapies: clinical landscape and manufacturing challenges. Regenerative medicine, 10(1), 49-64. https://doi.org/10.2217/rme.14.73
Heathman, Thomas R.J. ; Nienow, Alvin W. ; McCall, Mark J. ; Coopman, Karen ; Kara, Bo ; Hewitt, Christopher J. / The translation of cell-based therapies : clinical landscape and manufacturing challenges. In: Regenerative medicine. 2015 ; Vol. 10, No. 1. pp. 49-64.
@article{4f3cbad8820e4787a137c2d15d09ec5b,
title = "The translation of cell-based therapies: clinical landscape and manufacturing challenges",
abstract = "Cell-based therapies have the potential to make a large contribution toward currently unmet patient need and thus effective manufacture of these products is essential. Many challenges must be overcome before this can become a reality and a better definition of the manufacturing requirements for cell-based products must be obtained. The aim of this study is to inform industry and academia of current cell-based therapy clinical development and to identify gaps in their manufacturing requirements. A total of 1342 active cell-based therapy clinical trials have been identified and characterized based on cell type, target indication and trial phase. Multiple technologies have been assessed for the manufacture of these cell types in order to facilitate product translation and future process development.",
keywords = "bioreactor, cell-based therapy, clinical trials, manufacture, MSC, regenerative medicine, stem cell, translation",
author = "Heathman, {Thomas R.J.} and Nienow, {Alvin W.} and McCall, {Mark J.} and Karen Coopman and Bo Kara and Hewitt, {Christopher J.}",
note = "This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. Funding: EPSRC",
year = "2015",
doi = "10.2217/rme.14.73",
language = "English",
volume = "10",
pages = "49--64",
journal = "Regenerative medicine",
issn = "1746-0751",
publisher = "Future Medicine",
number = "1",

}

Heathman, TRJ, Nienow, AW, McCall, MJ, Coopman, K, Kara, B & Hewitt, CJ 2015, 'The translation of cell-based therapies: clinical landscape and manufacturing challenges', Regenerative medicine, vol. 10, no. 1, pp. 49-64. https://doi.org/10.2217/rme.14.73

The translation of cell-based therapies : clinical landscape and manufacturing challenges. / Heathman, Thomas R.J.; Nienow, Alvin W.; McCall, Mark J.; Coopman, Karen; Kara, Bo; Hewitt, Christopher J.

In: Regenerative medicine, Vol. 10, No. 1, 2015, p. 49-64.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The translation of cell-based therapies

T2 - clinical landscape and manufacturing challenges

AU - Heathman, Thomas R.J.

AU - Nienow, Alvin W.

AU - McCall, Mark J.

AU - Coopman, Karen

AU - Kara, Bo

AU - Hewitt, Christopher J.

N1 - This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. Funding: EPSRC

PY - 2015

Y1 - 2015

N2 - Cell-based therapies have the potential to make a large contribution toward currently unmet patient need and thus effective manufacture of these products is essential. Many challenges must be overcome before this can become a reality and a better definition of the manufacturing requirements for cell-based products must be obtained. The aim of this study is to inform industry and academia of current cell-based therapy clinical development and to identify gaps in their manufacturing requirements. A total of 1342 active cell-based therapy clinical trials have been identified and characterized based on cell type, target indication and trial phase. Multiple technologies have been assessed for the manufacture of these cell types in order to facilitate product translation and future process development.

AB - Cell-based therapies have the potential to make a large contribution toward currently unmet patient need and thus effective manufacture of these products is essential. Many challenges must be overcome before this can become a reality and a better definition of the manufacturing requirements for cell-based products must be obtained. The aim of this study is to inform industry and academia of current cell-based therapy clinical development and to identify gaps in their manufacturing requirements. A total of 1342 active cell-based therapy clinical trials have been identified and characterized based on cell type, target indication and trial phase. Multiple technologies have been assessed for the manufacture of these cell types in order to facilitate product translation and future process development.

KW - bioreactor

KW - cell-based therapy

KW - clinical trials

KW - manufacture

KW - MSC

KW - regenerative medicine

KW - stem cell

KW - translation

UR - http://www.scopus.com/inward/record.url?scp=84920747081&partnerID=8YFLogxK

U2 - 10.2217/rme.14.73

DO - 10.2217/rme.14.73

M3 - Article

AN - SCOPUS:84920747081

VL - 10

SP - 49

EP - 64

JO - Regenerative medicine

JF - Regenerative medicine

SN - 1746-0751

IS - 1

ER -